How to Buy Ascendis Pharma A Stock
Ascendis Pharma A
Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapeutics for unmet medical needs. The company offers SKYTROFA for treating patients with growth hormone deficiency (GHD).
Ascendis Pharma A stock last closed at $170.80, down 0.07% from the previous day, and has increased 33.6% in one year. It has overperformed other stocks in the Biotechnology industry by 1.1 percentage points. Ascendis Pharma A stock is currently +53.75% from its 52-week low of $111.09, and -6.67% from its 52-week high of $183.00.
There are currently 60.69M ASND shares outstanding. The market cap of ASND is $10.37B. In the past 24 hours, 370,000 ASND shares were traded.
How to Buy Ascendis Pharma A Stock
Not sure how to invest in Ascendis Pharma A stock? Here's how.
- Figure out where to buy Ascendis Pharma A stock: You need to choose an online brokerage, but don't worry - we've tried dozens of online stock brokerages and apps to help you figure out where to buy Ascendis Pharma A stock.
- Sign up for your brokerage account: Sign up for 0% commission trading with the highest-rated brokerage we've found.
- Deposit money your brokerage account: Pick your payment method and add your info.
- Research Ascendis Pharma A stock: The Ascendis Pharma A ticker symbol is ASND. Is Ascendis Pharma A stock a good investment? Should you buy shares of ASND? How do ASND's underlying business fundamentals look? Do top analysts think Ascendis Pharma A is a good buy? Why has ASND's stock price moved recently? (Hint: Our stock market research tools can help you figure out if ASND is a good stock to buy).
- Make your ASND trade: Decide if you will purchase ASND shares at the current market price or use a limit order to buy ASND stock at a specific price.
- Get updates on your investment in ASND: Create a watchlist to get the latest news on your position in Ascendis Pharma A shares.
Step 1: Figure out where to buy Ascendis Pharma A stock
You need an online brokerage account to access the NASDAQ market and buy ASND shares.
Our favorite brokerage: eToro
We believe that eToro is the best place to buy stocks. eToro gives you:
- Invest in stocks with zero commissions: Invest without commissions.
- Buy fractional shares: Even if you don't have the money to buy a full share, you can still buy the stock.
- Access to global financial markets: From Technology to Financial Services, New York to Hong Kong (for US users, only US stocks are available) — you can fill your portfolio with stocks from the world's leading stock exchanges.
- Social investing: eToro offers a community with more than 20 million users around the world. Talk to, learn from, and copy the crypto trades of top investors.
- Security: eToro is a regulated and licensed fintech leader.
- Buy other financial assets: Such as ETFs and cryptocurrencies.
Get $10 towards your share purchase by signing up for an account with eToro today. This offer is only for US users.
Open eToro AccountStep 2: Sign up for your brokerage account
Now that you've picked the right brokerage, you'll need to fill out some personal information so you can buy ASND stock today.
How to Set Up a New Investment Account on eToro
- Click here to get started.eToro is a multi-asset investment platform. The value of your investments may go up or down. Your capital is at risk.
- Input your personal data to start your new trading account.
- Submit your info by pressing the "Create Account" button. Get started with eToro today
Step 3: Deposit money your brokerage account
Now that you've filled out your info on the best stock broker app, your next step is to transfer the money for your investment:
Check out this video walkthrough for more details depositing funds into your new investment account.
Step 4: Research Ascendis Pharma A stock
After you have chosen the best place to buy Ascendis Pharma A stock, it's very important to evaluate their stock prior to investing, so you actually comprehend the risk and opportunity.
Ascendis Pharma A Metrics
Ascendis Pharma A Fundamentals
WallStreetZen was designed to help average investors perform better fundamental analysis in minutes instead of hours.
You can view all of the due diligence checks on ASND's stock page.
How is ASND stock valued?
You can use many financial metrics, analyses, models, and charts to gauge ASND's fair value.
You can access more valuation analysis on ASND's stock here.
ASND Financial Health Summary
Passed Financial Due Diligence Checks:
- There are more short-term assets than short-term liabilities on the ASND balance sheet.
- ASND has $588.55M in cash and short term investments. This is sufficient to cover its annual cash burn of $249.90M.
- There are more short-term assets than long-term liabilities on the ASND balance sheet.
- ASND has cash burn of 249896590. It has enough cash and short-term investments to cover this for at least one year.
Failed Financial Due Diligence Checks:
- ASND profit margin has gone up by 0.6 percentage points in the past year, but the company is still unprofitable.
- ASND debt to equity ratio of -6.59 is negative.
- Total ASND debt is still negative.
Is ASND stock a Buy, Hold, or Sell, according to analysts?
Out of 10 Equities analysts who track ASND, the consensus analyst rating on ASND is a Strong Buy
Please keep in mind that analyst ratings are not recommendations, nor are they financial advice.
Latest ASND Analyst Forecasts
Jessica Fye, a top 5% analyst from JP Morgan maintains ASND with a strong buy rating and raises their ASND price target from $200.00 to $245.00, on May 2, 2025.
JP Morgan's Jessica Fye raised their price target on Ascendis Pharma A (NASDAQ: ASND) by 22.5% from $200 to $245 on 2025/05/02. The analyst maintained their Strong Buy rating on the stock.
Ascendis Pharma A/S reported its Q1 2025 earnings.
Fye said they are "even more confident" in Yorvipath's trajectory after assessing the print.
The quarter's results were "impressive and set a strong foundation" for continued commercial execution in 2025 that will lead Ascendis Pharma A/S on a new trajectory, the analyst continued.
Fye added that JP Morgan now expects the company to reach operating profitability this year.
Earnings Report
For Q1 2025, Ascendis Pharma A/S reported:
- Loss per share of €1.58, which beat Q1 2024's €(2.30).
- Revenue from commercial products of €96.03M, which beat Q1 2024's €66.5M.
Management did not provide financial guidance in its press release.
President & CEO Jan Mikkelsen commented: “The strong global launch of YORVIPATH positions 2025 to be an inflection point for Ascendis with growing revenue and a path to cashflow breakeven in the near term.
"We look forward to potential approvals of our third product, TransCon CNP, as a monotherapy in children with achondroplasia, and we believe the upcoming topline COACH combination trial data may demonstrate improved outcomes, including growth, compared to TransCon CNP alone.
"With our diversified pipeline, robust supply chain, and strong global commercial capabilities we are well-positioned to deliver on our commitment to provide patients with highly differentiated medicines.”
Yun Zhong, a bottom 1% analyst from Wedbush maintains ASND with a buy rating and raises their ASND price target from $181.00 to $212.00, on May 2, 2025.
Joshua Schimmer, a top 2% analyst from Evercore ISI Group maintains ASND with a buy rating and raises their ASND price target from $260.00 to $280.00, on May 2, 2025.
Paul Choi, a bottom 10% analyst from Goldman Sachs maintains ASND with a strong buy rating and raises their ASND price target from $200.00 to $225.00, on Feb 13, 2025.
Eliana Merle, a top 22% analyst from UBS initiates coverage on ASND with a strong buy rating and announces their ASND price target of $196.00, on Jan 7, 2025.
You can dig deeper into what analysts are forecasting on the Ascendis Pharma A stock forecast page.
ASND Trading Indicators
ASND Performance Numbers
Last year, ASND revenue was $418.98M. Over the past five year, ASND's revenue has increased by 104.09% per year. This was faster than the Biotechnology industry average of 43.24%.
Find out more about ASND's earnings and revenue performance here.
What are ASND executives and large shareholders up to?
In the last 12 months, insiders at ASND have not bought or sold any shares.
Get more info about who owns ASND shares here.
Does ASND stock generate passive income?
No, Ascendis Pharma A doesn't provide an income stream by paying out dividends.
Get opinions from other investors
One of the primary reasons eToro is our highest-rated brokerage is because of its social trading community.
Click below to see what other traders have to say.
Step 5: Make your ASND trade
There are two main options:
- Market order: A market order is an order to buy or sell a security at the best price on the market.
Market orders are generally sufficient. - Limit order: A limit order lets you buy or sell a security at a specific price (or better).
If you want to ensure you're buying or selling at an exact dollar amount limit, place a limit order.
Press the Open button and your broker will execute the order.
If you want more info about investing in stocks on eToro, click the helpful video below:
Step 6: Get updates on your investment in ASND
Now that you own some shares in ASND, you'll want to stay up-to-date on your stock purchase.
Put ASND on a watchlist to see the latest developments about your ASND stock.
ASND Feed
How to Buy Stock in Ascendis Pharma A
To summarize, here are the 6 steps for buying Ascendis Pharma A stock:
- Figure out where to buy Ascendis Pharma A stock
- Sign up for your brokerage account
- Deposit money your brokerage account
- Research Ascendis Pharma A stock
- Make your ASND trade
- Get updates on your investment in ASND
If you need a brokerage account, eToro is our recommended option.
Get Started with eToro TodayIf you would like to keep tabs on your investment in Ascendis Pharma A, create a watchlist on WallStreetZen today.
Other Content You Might Enjoy
FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterInformation is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.